VYNE vs. NXTC, KZR, MNOV, HOOK, PRTK, GOSS, VERU, CRVS, CTMX, and ADAG
Should you be buying VYNE Therapeutics stock or one of its competitors? The main competitors of VYNE Therapeutics include NextCure (NXTC), Kezar Life Sciences (KZR), MediciNova (MNOV), Hookipa Pharma (HOOK), Paratek Pharmaceuticals (PRTK), Gossamer Bio (GOSS), Veru (VERU), Corvus Pharmaceuticals (CRVS), CytomX Therapeutics (CTMX), and Adagene (ADAG). These companies are all part of the "medical" sector.
VYNE Therapeutics (NASDAQ:VYNE) and NextCure (NASDAQ:NXTC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, community ranking, dividends, earnings, institutional ownership and profitability.
NextCure has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -6,874.47%. NextCure's return on equity of -53.29% beat VYNE Therapeutics' return on equity.
VYNE Therapeutics has higher revenue and earnings than NextCure. NextCure is trading at a lower price-to-earnings ratio than VYNE Therapeutics, indicating that it is currently the more affordable of the two stocks.
83.8% of VYNE Therapeutics shares are owned by institutional investors. Comparatively, 42.7% of NextCure shares are owned by institutional investors. 1.8% of VYNE Therapeutics shares are owned by insiders. Comparatively, 13.3% of NextCure shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
VYNE Therapeutics has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500. Comparatively, NextCure has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500.
VYNE Therapeutics currently has a consensus price target of $5.75, suggesting a potential upside of 155.56%. NextCure has a consensus price target of $6.00, suggesting a potential upside of 331.65%. Given NextCure's higher possible upside, analysts plainly believe NextCure is more favorable than VYNE Therapeutics.
In the previous week, VYNE Therapeutics had 2 more articles in the media than NextCure. MarketBeat recorded 2 mentions for VYNE Therapeutics and 0 mentions for NextCure. VYNE Therapeutics' average media sentiment score of 0.00 equaled NextCure'saverage media sentiment score.
NextCure received 53 more outperform votes than VYNE Therapeutics when rated by MarketBeat users. Likewise, 63.93% of users gave NextCure an outperform vote while only 59.52% of users gave VYNE Therapeutics an outperform vote.
Summary
NextCure beats VYNE Therapeutics on 9 of the 15 factors compared between the two stocks.
Get VYNE Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VYNE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VYNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
VYNE Therapeutics Competitors List
Related Companies and Tools
